Neximmune Inc (NEXI)

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial...  Immune Modulation, a vivo directly injectable modality platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.  और पढ़ें

• CEO, President & Director

  Ms. Kristi Jones R.Ph.

• CEO, President & Director

  Ms. Kristi Jones R.Ph.

• हेडक्वार्टर्स

  Gaithersburg, MD

• वेबसाइट

  https://www.neximmune.com